Needham analyst Gil Blum maintained a Buy rating on I-MAB today and set a price target of $6.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gil Blum has given his Buy rating due to a combination of factors related to I-Mab’s strategic decisions and promising clinical developments. The company is expanding the clinical development of its drug, givastomig, to target additional tumor types, including pancreatic and biliary tract cancers, which could open new avenues for growth. Furthermore, I-Mab is conducting a Phase Ib study to evaluate the efficacy of givastomig combined with chemotherapy in a specific patient group with poor outcomes, indicating a targeted approach to address unmet medical needs.
Another reason for the Buy rating is I-Mab’s strong financial position, bolstered by recent financing that ensures operational runway through the fourth quarter of 2028. This financial stability supports the company’s ongoing and future clinical trials. Additionally, the positive initial results from givastomig’s dose escalation study earlier this year further justify the company’s focus on this drug. The anticipated commencement of a randomized Phase II trial and the guidance for topline progression-free survival data in 2027 also contribute to the positive outlook for I-Mab’s stock.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, I-MAB, and Rocket Pharmaceuticals. According to TipRanks, Blum has an average return of 0.0% and a 37.93% success rate on recommended stocks.
In another report released on August 28, Brookline Capital Markets also maintained a Buy rating on the stock with a $8.00 price target.